MedPath
FDA Approval

Omnipaque

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
GE Healthcare
DUNS: 053046579
Effective Date
May 5, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Iohexol(300 mg in 1 mL)

Manufacturing Establishments3

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

GE Healthcare Ireland Limited

GE Healthcare

988006565

GE Healthcare Lindesnes

GE Healthcare

518890970

GE Healthcare Shanghai Co., Ltd.

GE Healthcare

545292716

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Omnipaque

Product Details

NDC Product Code
0407-1413
Application Number
NDA020608
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
April 30, 2023
IohexolActive
Code: 4419T9MX03Class: ACTIRQuantity: 300 mg in 1 mL
edetate calcium disodiumInactive
Code: 25IH6R4SGFClass: IACTQuantity: 0.1 mg in 1 mL
sodium hydroxideInactive
Code: 55X04QC32IClass: IACT
tromethamineInactive
Code: 023C2WHX2VClass: IACTQuantity: 1.21 mg in 1 mL
hydrochloric acidInactive
Code: QTT17582CBClass: IACT

Omnipaque

Product Details

NDC Product Code
0407-1414
Application Number
NDA020608
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
April 30, 2023
tromethamineInactive
Code: 023C2WHX2VClass: IACTQuantity: 1.21 mg in 1 mL
IohexolActive
Code: 4419T9MX03Class: ACTIRQuantity: 350 mg in 1 mL
sodium hydroxideInactive
Code: 55X04QC32IClass: IACT
hydrochloric acidInactive
Code: QTT17582CBClass: IACT
edetate calcium disodiumInactive
Code: 25IH6R4SGFClass: IACTQuantity: 0.1 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath